Form 4: Amphastar Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Amphastar Pharmaceuticals Director Floyd F. Petersen sold 500 shares of common stock for $30.9833 per share as part of a pre-arranged trading plan.
Summary
- Floyd F. Petersen, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), sold 500 shares of common stock.
- The transaction occurred on September 2, 2025, at a weighted average price of $30.9833 per share.
- The shares were sold in multiple transactions ranging from $30.60 to $31.225.
- This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Petersen on November 26, 2024.
- Following the transaction, Mr. Petersen directly beneficially owns 76,531 shares of Amphastar common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a Rule 10b5-1 plan mitigates any negative signal, as it indicates a pre-scheduled transaction for personal financial management rather than a reaction to new company developments. The amount sold (500 shares) is also relatively small.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, non-discretionary transaction rather than a reaction to new information.
Negatives
- A director's sale of shares, even under a 10b5-1 plan, reduces their direct ownership stake in the company.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Insider sales are common in the pharmaceutical industry, often for personal financial planning, especially when executed under pre-arranged 10b5-1 plans.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | NA | NA | NA | No management changes reported; this filing is about a transaction by an existing director. |
Stakeholder Impact
- Shareholders: The sale of a small number of shares by a director under a 10b5-1 plan is unlikely to have a significant impact on the company's stock price or investor sentiment, as it is a routine personal financial transaction.
Key Dates
| Date | Description |
|---|---|
| 11/26/2024 | Date Rule 10b5-1 trading plan was adopted by Floyd F. Petersen. |
| 09/02/2025 | Date of common stock transaction by Floyd F. Petersen. |
| 09/03/2025 | Date the Form 4 was signed and filed. |
Keywords
Amphastar Pharmaceuticals, AMPH, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Equity Transaction, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.